Skip to main content

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Providing Reliable, Consistent Dose Administration and Monitoring Devices

RYAH Group (CSE: RYAH), a connected device and big data and technology company, offers a suite of precision intake control and management devices that provide a practical way to execute volume control guidelines safely. In a company blog post, discussed in a recent article, RYAH noted that a global task force had created three separate dosing protocols: routine administration, conservative administration and rapid administration, with each designed to ease a patient treating chronic pain into medical cannabis and treatment with THC if needed. Such dosing guidelines are just half of the equation. The other half is the delivery mechanism, as patients need a reliable way to receive consistent and measurable doses to adhere to their treatment protocols. Physicians also need a way to monitor patent titration and dose size. This is where RYAH Group’s devices come in. “The RYAH Smart Patch, Inhaler and Pen enable patients and physicians to control their medicine, the specific administration volume and the protocol behind the treatment. In addition, detailed analytics provided by these RYAH devices help determine which intake volumes are working and what needs adjusting, and a patient’s progress in their treatment.”

To view the full article, visit https://ibn.fm/qAI0k

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information, visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.